Shifting Medicine Forward

Our path toward disease-centric therapies

Oncology Pipeline

Products	Description	Preclinical	Phase 1	Phase 2	Phase 3	Status
ISB 1342	CD38 x CD3 BEAT® 1.0 bispecific antibody	Multiple Myeloma; T-ALL under consideration*				Phase 1 Orphan Drug
ISB 1442	CD38 x CD47 BEAT® 2.0 bispecific antibody	Multiple Myeloma; Phase 1 Acute Myeloid Leukemia (AML) planned				PHASE 1 Orphan Drug
ISB 2001	BCMA x CD38 x CD3 TREAT™ trispecific antibody	Multiple Myeloma				PHASE 1

Oncology Pipeline

Compound:

ISB 1342

Target:

CD38 x CD3
BEAT^® 1.0 bispecific antibody

Indication:

Multiple Myeloma;
T-ALL under consideration*

Phase:

phase-1

Status:

Phase 1 Orphan Drug

Compound:

ISB 1442

Target:

CD38 x CD47 BEAT^® 2.0 bispecific antibody

Indication:

Multiple Myeloma;
Phase 1 Acute Myeloid
Leukemia (AML) planned

Phase:

phase-1

Status:

PHASE 1 Orphan Drug

Compound:

ISB 2001

Target:

BCMA x CD38 x CD3 TREAT™ trispecific antibody

Indication:

Multiple Myeloma

Phase:

phase-1

Status:

PHASE 1

BEAT^®: Bispecific Engagement by Antibodies based on the T-cell receptor
TREAT™: Trispecific Engagement by Antibodies based on the T-cell receptor

Autoimmune Disease

Products	Description	Preclinical	Phase 1	Phase 2	Phase 3	Status
ISB 830 (telazorlimab) (Licensing discussions ongoing)	OX40 antagonist monoclonal antibody	Atopic Dermatitis (AD)*				Phase 2b completed†
ISB 880 / ALM27134 (Licensed to Almirall S.A.)	IL-1RAP antagonist monoclonal antibody	Autoimmune Disease				Phase 1

Autoimmune Disease

Compound:

ISB 830 (telazorlimab) (Licensing discussions ongoing)

Target:

OX40 antagonist monoclonal antibody

Indication:

Atopic Dermatitis (AD)*

Phase:

phase-2

Status:

Phase 2b completed^†

Compound:

ISB 880 / ALM27134 (Licensed to Almirall S.A.)

Target:

IL-1RAP antagonist monoclonal antibody

Indication:

Autoimmune Disease

Phase:

phase-1

Status:

Phase 1

*A US IND for rheumatoid arthritis and other autoimmune indications is active.

^†Primary efficacy endpoint (EASI score, % change, baseline to week 16) met at two highest doses tested. Numerical improvements were seen for the two higher-dose arms (300 mg and 600 mg q 2 weeks) of telazorlimab compared to placebo in the secondary endpoints of EASI-75 and Investigator Global Assessment, but the differences were generally not statistically significantly different from placebo.

Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.